Skip to main content

Table 8 Results of Pure Tone Audiometry

From: Cisplatin-associated ototoxicity: perspectives from a single institution cervical cancer cohort and implications for developing a locally responsive monitoring programme in a public healthcare setting

 

Baseline

Mid-cycle

One month post treatment

Three-month post treatment

Six-month post treatment

Number of participants presenting with hearing loss, n (%)

 Both ears

17(20.7)

21 (25.6)

24 (29.2)

24 (29.2)

31 (37.8)

 Left ear only

6 (7.3)

7 (8.5)

4 (4.9)

10 (12.2)

10 (12.2)

 Right ear only

5 (6.1)

6 (7.3)

6 (7.3)

5 (6.1)

3 (3.7)

Degree of Hearing Loss, n (%)

 Right ear

  Normal

60 (73.2)

55 (67.1)

51 (62.2)

51 (63.8)

46 (56.1)

  Mild

8 (9.8)

8 (9.8)

11 (13.4)

8 (9.8)

11 (13.4)

  Mild-to-moderate

7 (8.5)

9 (11.0)

9 (11.0)

12 (14.6)

13 (15.9)

  Mild-to- moderately severe

5 (6.1)

7 (8.5)

5 (6.1)

6 (7.3)

6 (7.3)

  Mild-to-severe

1 (1.2)

0 (0)

1 (1.2)

1 (1.3)

1 (1.3)

  Mild-to-profound

1 (1.2)

0 (0)

1 (1.2)

1 (1.3)

1 (1.3)

  Moderate-to-moderately severe

0 (0)

0 (0)

0 (0)

1 (1.3)

1 (1.3)

  Moderate-to- profound

0 (0)

1 (1.2)

1 (1.2)

1 (1.3)

1 (1.3)

 Left ear

  Normal

59 (72)

54 (65.9)

53 (64.6)

46 (57.5)

41 (51.3)

  Mild

8 (9.8)

11 (13.4)

10 (12.2)

17 (20.7)

16 (19.5)

  Mild-to-moderate

6 (7.3)

8 (9.8)

9 (11.0)

7 (8.6)

8 (9.8)

  Mild-to-moderately severe

3 (3.7)

4 (4.9)

4 (4.9)

6 (7.3)

9 (11.0)

  Mild-to-severe

3 (3.7)

3 (3.7)

3 (3.7)

3 (3.7)

3 (3.7)

  Moderate

1 (1.2)

0 (0)

0 (0)

0 (0)

0 (0)

  Moderate-to-moderately severe

0 (0)

0 (0)

0 (0)

0 (0)

2 (2.4)

  Severe-to-profound

2 (2.4)

2 (2.4)

1 (1.2)

1 (1.2)

1 (1.2)

Types of Hearing Loss

 Sensorineural

  Right ear

21 (25.6)

25 (30.5)

28 (34.1)

28 (34.2)

33 (40.2)

  Left ear

22 (26.8)

27 (32.9)

27 (32.9)

34 (41.5)

39 (47.6)

 Mixed

  Right ear

1 (1.2)

2 (2.4)

1 (1.2)

1 (1.2)

1 (1.2)

  Left ear

1 (1.2)

1 (1.2)

0 (0)

0 (0)

0 (0)